Name:

Nimenrix

Abbreviation:

MenACWY (Meningococcal Conjugate Vaccine for ACWY Serogroups)

General Overview:

Nimenrix is an inactivated vaccine considered one of the key preventive measures against meningococcal infections.

The vaccine is produced using advanced biotechnological methods - it contains polysaccharide antigens from meningococcal groups A, C, W, and Y conjugated to a protein matrix to enhance the immune response.

Nimenrix does not contain live microorganisms and is manufactured as a lyophilized powder and solvent, ensuring vaccine stability and effectiveness.

The vaccine is stored at 2°C to 8°C and must not be frozen; it is presented in pre-filled syringes, which simplifies the injection process and ensures accurate dosing.

Nimenrix’s safety and immunogenicity have been confirmed by multiple clinical studies across various age groups, making it widely used for protection against meningococcal infections.